denosumab

The drug is used for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. It is also prescribed for the treatment of bone loss in men receiving hormone suppression therapy for prostate cancer, and for adults experiencing bone loss due to long-term glucocorticoid use.

Form: solution for injection

ATC: M05BX04

Manufacturer: Novartis Pharmaceutical Manufacturing GmbH (full production cycle; batch control)

The drug is indicated for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. It is also used to treat bone loss in men receiving hormone suppression therapy for prostate cancer, and in patients with bone loss due to long-term glucocorticoid therapy.

Form: solution for injection

ATC: M05BX04

Manufacturer: Amgen Manufacturing Limited (manufacturing unpackaged products, primary packaging)

The drug is used for adults with advanced-stage malignant bone tumors to prevent events such as pathological fractures, bone irradiation, spinal cord compression, or surgical intervention on the bones. Vaest is also prescribed to adults and children with mature skeletal systems for the treatment of giant cell bone tumors that cannot be surgically removed without severe consequences.

Form: solution for injection

ATC: M05BX04

Manufacturer: Lek Pharmaceutical Company d.d. (full production cycle)

The drug is used to prevent skeletal-related events (such as pathological fractures, the need for bone radiation, surgical intervention on bones, or spinal cord compression) in adults with late-stage malignant tumors that affect the bones. It is also indicated for the treatment of adults and adolescents with mature skeletal systems who have giant cell bone tumors, if they cannot be surgically removed or if surgery poses a risk of severe consequences.

Form: solution for injection

ATC: M05BX04

Manufacturer: Amgen Manufacturing Limited (manufacturer of unpackaged product, primary packaging)